Acrivon Therapeutics, Inc.
ACRV
$1.49
-$0.155-9.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.58% | 24.87% | 56.69% | 85.58% | 142.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.93% | 52.33% | 54.34% | 76.66% | 105.48% |
| Operating Income | -32.93% | -52.33% | -54.34% | -76.66% | -105.48% |
| Income Before Tax | -33.40% | -53.75% | -54.03% | -74.69% | -93.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.40% | -53.75% | -54.03% | -74.69% | -93.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.40% | -53.75% | -54.03% | -74.69% | -93.76% |
| EBIT | -32.93% | -52.33% | -54.34% | -76.66% | -105.48% |
| EBITDA | -32.49% | -52.20% | -54.40% | -77.04% | -106.13% |
| EPS Basic | 10.84% | -0.96% | 61.53% | 70.76% | 79.53% |
| Normalized Basic EPS | 10.97% | -0.35% | 61.35% | 70.58% | 79.37% |
| EPS Diluted | 10.84% | -0.96% | 61.53% | 70.76% | 79.53% |
| Normalized Diluted EPS | 10.97% | -0.35% | 61.35% | 70.58% | 79.37% |
| Average Basic Shares Outstanding | 52.95% | 54.62% | 81.70% | 143.36% | 438.10% |
| Average Diluted Shares Outstanding | 52.95% | 54.62% | 81.70% | 143.36% | 438.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
